Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026

Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) will release third quarter 2026 financial results before U.S. markets open on November 12, 2026.

Rhea-AI Summary

Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) will release third quarter 2026 financial results before U.S. markets open on November 12, 2026.

Management will host a conference call and webcast that day at 8:30 a.m. Eastern Time to discuss financial and business results. A webcast replay will be available on the company’s website for thirty days.

Key Terms

ototoxicity, orphan drug exclusivity, pediatric use marketing authorization

3 terms

ototoxicity medical

"committed to the fight against ototoxicity in cancer patients"

Ototoxicity is damage to the inner ear caused by certain drugs or chemicals that can impair hearing and balance, ranging from temporary ringing to permanent hearing loss. Investors should care because ototoxic effects can limit a medical product’s marketability, trigger stricter safety testing, slow approvals, increase legal and treatment costs, and hurt sales—similar to a car defect that makes a model unsafe and forces recalls or redesigns.

orphan drug exclusivity regulatory

"PEDMARK has received Orphan Drug Exclusivity in the U.S."

A regulatory right that gives a drugmaker sole approval to market a medicine for a specific rare disease for a set number of years, during which the regulator will not approve the same medicine from competitors for that same use. For investors, this is like a temporary exclusive sales permit that can protect revenue and justify higher valuation because it reduces near‑term competition and helps the company recover development costs and capture market share.

pediatric use marketing authorization regulatory

"PEDMARQSI has received Pediatric Use Marketing Authorization in Europe"

A pediatric use marketing authorization is a regulatory approval that allows a drug or medical product to be sold and labeled specifically for use in children after authorities review pediatric safety, dosing and effectiveness data. It matters to investors because it opens a separate market segment, can change sales forecasts and regulatory risk, and may affect exclusivity or competition much like obtaining a new license to serve an additional group of customers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, November 12, 2026. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.

Conference Call & Webcast Detail:

Date: Thursday, November 12, 2026
Time: 8:30 a.m. Eastern Time
Webcast Link: https://edge.media-server.com/mmc/p/vuhn59ek
Participant Link: https://register-conf.media-server.com/register/BIa5435e66b82346329a08be7e156e3eac

To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.

About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK^® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI.

In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI^® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in multiple countries.

PEDMARK has received Orphan Drug Exclusivity in the U.S. and.; PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally.

For more information, please visit www.fennecpharma.com and follow on LinkedIn.

For further information, please contact:

Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299

Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com